CASE WESTERN RESERVE UNIVERSITY

Extended follow-up of DeLLphi-300 trial shows tarlatamab, a bispecific T-cell engager, benefits previously treated small cell lung cancer patients with 25.0% objective response rate, 11.2 months median duration of response, and 17.5 months median overall survival. At recommended 10 mg every 2 weeks, 35.3% response rate, 14.9 months median duration, 20.3 months median survival, and 29.4% sustained disease control at ≥ 52 weeks. Intracranial activity observed in 62.5% with baseline CNS lesions ≥ 10 mm.

Ohio's business ties with Israel, particularly in biotechnology, are deep-rooted, despite the state's lagging economic growth. Cleveland's medical institutions collaborate with Israeli counterparts, funded by Zionist philanthropists, raising ethical concerns. Despite scandals, pro-Zionist agendas persist in local power structures, but resistance from a human rights movement is emerging.

The Clinical and Translational Science Collaborative (CTSC) of Northern Ohio hosts a Science Cafe on Sept. 12, featuring Princess Ogbou discussing 'Enhancing the Impact of Clinical Trials' through the Trial Innovation Network (TIN), aiming to accelerate novel interventions into therapies.

Robert Salata, MD, a distinguished alumnus of Case Western Reserve University and a prominent figure at University Hospitals, passed away at 72. His contributions to infectious diseases research, including leading clinical trials for COVID-19 treatments, left a profound impact on global health. Salata was instrumental in establishing a research hub in Uganda, fostering generations of physicians through mentorship.